<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635127</url>
  </required_header>
  <id_info>
    <org_study_id>USZ-DER-AAN-017</org_study_id>
    <nct_id>NCT01635127</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Canakinumab to Treat Urticaria</brief_title>
  <acronym>URTICANA</acronym>
  <official_title>A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation whether canakinumab leads to improvement of urticaria&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center prospective placebo-controlled cross-over phase II study.&#xD;
&#xD;
        -  To assess if canakinumab can induce clinical improvement and/or complete clinical&#xD;
           remission of chronic idiopathic urticaria at week 4 as compared to placebo&#xD;
&#xD;
        -  To compare canakinumab and placebo treated patients in the percentage who achieve&#xD;
           complete clinical remission at week 1, 2, 4, and 8.&#xD;
&#xD;
        -  To compare the percentage with clinical improvement as measured by UAS7 score at week 1,&#xD;
           2, 4, and 8 in canakinumab and placebo treated patients&#xD;
&#xD;
        -  To compare the percentage of canakinumab and placebo treated patients with 75% and 100%&#xD;
           improvement of their baseline (Run-in-period) UAS7 score at week 1,2,4,and 8&#xD;
&#xD;
        -  To compare the daily wheal score for Days 1 to 7 in canakinumab and placebo treated&#xD;
           patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical remission</measure>
    <time_frame>4 weeks</time_frame>
    <description>Improvement of urticaria within 4 weeks, objective measurements daily wheal score and UAS7</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Idiopathic Urticaria</condition>
  <arm_group>
    <arm_group_label>Canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monoclonal antibody inhibiting interleukin 1 beta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Constituent, inactive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab</intervention_name>
    <description>150mg s.c.</description>
    <arm_group_label>Canakinumab</arm_group_label>
    <other_name>Ilaris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Constituent of canakinumab</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Diagnosis of chronic idiopathic urticaria for more than 6 weeks as confirmed by&#xD;
             clinical and, if necessary, histological examination&#xD;
&#xD;
          -  CIU of moderate to severe severity defined by all of the following&#xD;
&#xD;
               -  Physician severity score of 2 or 3 (on a scale from 0 - 3)&#xD;
&#xD;
               -  Run-in period of the diary-based UAS7 score of &gt; 21 (on a scale from 0 - 42)&#xD;
&#xD;
               -  Symptomatic despite use of non-sedating antihistamine with or without concomitant&#xD;
                  leukotriene antagonist/corticosteroids&#xD;
&#xD;
          -  Use of maintenance non-sedating antihistamine at a stable dose for at least 1 week&#xD;
             prior to entering run-in period&#xD;
&#xD;
          -  Maintenance corticosteroids at a dose of &lt;20 mg/day or &lt;0.4 mg/kg stable for at least&#xD;
             the week prior to study entry for treatment of the patient's CIU will be allowed.&#xD;
&#xD;
          -  Age: &gt; 18 years.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Negative or unreactive QuantiFERON test (QFT-TB G In-Tube) or history of adequate&#xD;
             treatment of active or latent tuberculosis.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 70 years&#xD;
&#xD;
          -  History of cancer except for treated basal cell carcinoma of the skin&#xD;
&#xD;
          -  With active or recurrent bacterial, fungal or viral infection at the time of&#xD;
             enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV)&#xD;
             infection, Hepatitis B and Hepatitis C infection, active or untreated latent&#xD;
             tuberculosis.&#xD;
&#xD;
          -  Patients currently treated with systemic immunosuppressive agents or following&#xD;
             treatments in the specified period before the baseline visit:&#xD;
&#xD;
               -  corticosteroids =20 mg/day or &gt;0.4 mg/kg for 1 week prior to study entry;&#xD;
&#xD;
               -  leukotriene antagonists for 1 week prior to study entry&#xD;
&#xD;
               -  colchicine, dapsone or mycophenolate mofetil for 3 weeks;&#xD;
&#xD;
               -  etanercept, leflunomide (documentation of a completion of a full cholestyramine&#xD;
                  elimination treatment after most recent leflunomide use will be required),&#xD;
                  thalidomide or ciclosporin for 4 weeks;&#xD;
&#xD;
               -  adalimumab or intravenous immunoglobulin for 8 weeks;&#xD;
&#xD;
               -  infliximab, 6-mercaptopurine, azathioprine, cyclophosphamide or chlorambucil for&#xD;
                  12 weeks&#xD;
&#xD;
          -  Live vaccinations within 3 months prior to the start of the trial, during the trial,&#xD;
             and up to 3 months following the last dose&#xD;
&#xD;
          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or&#xD;
             allergy to class of drugs or the investigational product,&#xD;
&#xD;
          -  Pregnant or lactating women, patients (men or women) planning a pregnancy during the&#xD;
             duration of the study, lack of safe contraception.&#xD;
&#xD;
          -  Safe contraception is defined as follows:&#xD;
&#xD;
          -  Double-barrier contraception such as oral, injectable, or implantable contraceptives,&#xD;
             or intrauterine contraceptive devices together with condom use.&#xD;
&#xD;
          -  Both men and women must use safe contraception (double-barrier as defined above)&#xD;
             during the duration of the study and until 6 months after the study.&#xD;
&#xD;
          -  Please note that female subjects who are surgically sterilized/hysterectomized or&#xD;
             post-menopausal for longer than 2 years are not considered as being of child bearing&#xD;
             potential.&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the subject.&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study.&#xD;
&#xD;
          -  Previous enrolment into the current study.&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Schmid-Grendelmeier, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonios Kolios, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>antonios.kolios@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Navarini, MD PhD</last_name>
    <email>alexander.navarini@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Dermatology</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Chronic Urticaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

